Summary
The pharmacokinetics of vinorelbine has been investigated by a new HPLC method in 8 cancer patients receiving 8 weekly doses (30 mg·m−2) administered by brief infusion (15 min).
The plasma concentration-time curves showed a tri-exponential decay with a long terminal half-life (44.7 h) and a high volume of distribution (Vz=75.61·kg−1). The concentrations after the 8th infusion were significantly lower than after the 1st infusion, but without significant modification of CL (1.28 l·h−1·kg−1) or AUC (0.80 mg·l−1·h).
The pharmacokinetic parameters exhibited wide inter-individual variations. The results are consistent with those of previous RIA studies, although the HPLC method appears to be more specific and more precise.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mangeney P, Andriamialisoa RZ, Lallemand JY, Langlois N, Langlois Y, Potier P (1979) 5'-noranhydrovinblastine. Prototype of a new class of vinblastine derivatives. Tetrahedron 35: 2175–2179
Mangeney P, Andriamialisoa RZ, Lallemand JY, Langlois N, Langlois Y, Potier P (1979) A new class of antitumor compounds: 5'-nor and 5',6'-seco derivatives of vinblastine-type alkaloids. J Org Chem 44: 3765–3768
Rahmani R, Martin M, Barbet J, Cano JP (1984) Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (Navelbine). Cancer Res 44: 5609–5613
Ribaud P, Gouveia J, Maral R, Potier P, Jasmin C, Mathé G (1981) Phase I study of noranhydrovinblastine (Navelbine, NVB). Abstract publication. Proc Am Assoc Cancer Res 22: 368
Favre R, Garnier G, Depierre A, Samak R, Cano JP, Carcassonne Y (1985) A phase I study of Navelbine(nor-5' anhydrovinblastine). In: Ishigami J (ed) 14th International Congress of Chemotherapy. International Society of Chemotherapy. University of Tokyo Press. Tokyo, Japan, pp 343
Rahmani R, Guéritte F, Martin M, Just S, Cano JP, Barbet J (1986) Comparative pharmacokinetics of antitumor vinca alkaloids: intravenous bolus injections of Navelbine and related alkaloids to cancer patients and rats. Cancer Chemother Pharmacol 16: 223–228
Rahmani R, Bruno R, Iliadis A, Favre R, Just S, Barbet J, Cano JP (1987) Clinical pharmacokinetics of the antitumor drug Navelbine (5'-noranhydrovinblastine). Cancer Res 47: 5796–5799
Krikorian A, Rahmani M, Bromet M, Boré P, Cano JP (1989) Pharmacokinetics and metabolism of navelbine. Semin Oncol 16 [Suppl 4]: 21–25
Nicot G, Lachatre G, Marquet P, Bonnaud F, Valette JP, Rocca JL (1990) High performance liquid chromatographic determination of Navelbine in human plasma and urine. J Chromatogr 528: 258–266
Aronson JK, Dengler HJ, Dettli L, Follath F (1988) Standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol 35: 1–7
Boré P, Rahmani R, Van Cantfort J, Focan C, Cano JP (1989) Pharmacokinetics of a new anticancer drug, Navelbine, in patients. Cancer Chemother Pharmacol 23: 247–251
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marquet, P., Lachatre, G., Debord, J. et al. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 42, 545–547 (1992). https://doi.org/10.1007/BF00314866
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314866